Merck Sets its Sights on 2018 and Outlines Future Strategic Roadmap
• Merck on track to achieve objectives for 2018
• Pharma pipeline offers new sales potential of around € 2 billion up to 2022
• Sigma-Aldrich integration will exceed synergy targets by € 20 million thanks to additional top-line synergies
• Performance Materials strengthens its market position through investments and is planning the launch of a new liquid crystal technology
• Oschmann: “We want to remain a leader at the forefront of scientific and technological progress”
Darmstadt, Germany – Merck, a leading science and technology company, today informed analysts and investors at its 2016 Capital Market Day about the progress it has made in achieving its objectives up to the year 2018. In addition, CEO Stefan Oschmann and CFO Marcus Kuhnert provided a look at the period after 2018, the year which marks the company’s 350th anniversary.
“We firmly believe that we will meet the objectives we have set for 2018,” said Stefan Oschmann, Chairman of the Executive Board a